TAS 102

DRUG9 trials

Conditions

Bladder CancerColorectal CancerGastric AdenocarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaMetastasisMetastatic Adenocarcinoma of the Gastroesophageal JunctionPancreas Cancer

Phase 1

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

CompletedNCT03305913

AIO-Studien-gGmbHPretreated Metastatic Colorectal Cancer

Start: 2017-07-31End: 2019-04-26Updated: 2021-03-26

Phase 2

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

CompletedNCT03686488

H. Lee Moffitt Cancer Center and Research InstituteGastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2018-12-20End: 2024-05-31Updated: 2026-03-02

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

NCT03762161

Rahul ParikhBladder Cancer

Start: 2019-01-03End: 2024-01-31Target: 22Updated: 2022-03-10

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

NCT03909724

Amsterdam UMC, location VUmcColorectal Cancer, Metastasis

Start: 2019-10-01End: 2022-07-01Target: 60Updated: 2020-11-13

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

CompletedNCT04417699

Providence Health & ServicesRectal Cancer

Start: 2022-07-05End: 2024-02-21Updated: 2025-12-10

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

CompletedNCT04923529

The University of Hong KongPancreas Cancer

Start: 2021-03-01End: 2024-12-31Updated: 2025-07-18

TAS-102 and Anlotinib in ≥3 Lines mGC

RecruitingNCT05029102

Zhejiang UniversityGastric Cancer

Start: 2021-09-01End: 2024-12-31Target: 45Updated: 2024-02-12

Phase 3

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

CompletedNCT03520946

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestColorectal Cancer

Start: 2019-01-24End: 2024-07-30Updated: 2024-08-09

Unknown Phase

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

CompletedNCT04517747

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestGastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction

Start: 2020-10-15End: 2023-01-20Updated: 2023-02-10

Journal of Clinical Oncology2026-05-27

A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas.

2025-12-01

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma.

2025-10-01

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer

ESMO Gastrointestinal Oncology2025-08-08

Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system

BMJ Open2024-11-01

Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study.

Journal of Clinical Oncology2023-01-242 citations

A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).

Journal of Clinical Oncology2022-01-192 citations

RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).

Journal of Clinical Oncology2021-05-201 citations

Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY).

Journal of Clinical Oncology2020-02-016 citations

A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Journal of Clinical Oncology2019-05-202 citations

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

Journal of Clinical Oncology2019-05-201 citations